Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
WARRINGTON, Pa. , April 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the pricing of its underwritten public offering
Article Date
April 20, 2023
This article is featured on another website.
Go to article
August 26, 2026
Asia’s Shifting Regulatory Map: What Sponsors Need to Know Before Choosing a Trial Location
Part 3 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
August 26, 2026
Asia’s Shifting Regulatory Map: What Sponsors Need to Know Before Choosing a Trial Location
Part 3 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…